BACKGROUND: In heart failure (HF), digoxin at low serum digoxin concentrations (SDC)
reduces all-cause mortality and HF hospitalizations. However, the effects of digoxin on other …

Context The Digitalis Investigation Group (DIG) trial reported that digoxin provided no overall
mortality benefit and only a modest reduction in hospitalizations among patients with heart …

Aims To determine the effects of digoxin on all-cause mortality and heart failure (HF)
hospitalizations, regardless of ejection fraction, accounting for serum digoxin concentration …

Objectives: We sought to determine whether there was a relationship between serum
digoxin concentration (SDC), including SDCs typically regarded as low, and clinical efficacy …

Discontinuation of digoxin is associated with worsening heart failure (HF) symptoms.
However, the long-term effects of discontinuation of digoxin therapy on mortality and …

Aims In the Digitalis Investigation Group (DIG) trial, digoxin reduced mortality or
hospitalization due to heart failure (HF) in several pre‐specified high‐risk subgroups of HF …

Post hoc analyses of the Digitalis Investigation Group (DIG) trial indicate that digoxin at low
(0.5 to 0.9 ng/ml) serum digoxin concentration (SDC) reduces mortality, which is eliminated …

Aims Many patients with heart failure and reduced EF remain at high risk for hospitalization
despite evidence‐based therapy. Digoxin may decrease hospitalization; however …

Background The role of cardiac glycosides in treating patients with chronic heart failure and
normal sinus rhythm remains controversial. We studied the effect of digoxin on mortality and …

Background. Digoxin reduces hospitalizations due to heart failure (HF) and may also reduce
mortality at low serum digoxin concentrations (SDC). Most HF patients are≥ 65 years, yet …